Ultrasensitive circulating tumor DNA detection improves prognostication in triple-negative breast cancer postneoadjuvant therapy.

L Cabel¹, C Lamy², C W Abbott³, K C Keough³, N Pouget⁴, J-Y Pierga⁵, M-P Sablin², J Flavius², T Bronzini⁶, E Laas⁴, L Darrigues⁴, B Li³, F C P Navarro³, J-G Féron⁴, V Fourchotte⁴, C Bonneau⁷, A Vincent-Salomon⁸, S M Boyle³, R O Chen³, C Le Tourneau⁹, F-C Bidard¹⁰

¹Department of Medical Oncology, Institute Curie, Paris and Saint-Cloud, France; Circulating Tumor Biomarkers Laboratory, CIC Inserm 1428, Paris, France.

²Department of Drug Development and Innovation (D3i), Institut Curie, Paris-Saclay University, Paris, France.

³Personalis, Inc, Fremont, California, USA.

⁴Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Paris and Saint-Cloud, France.

⁵Department of Medical Oncology, Institute Curie, Paris and Saint-Cloud, France; Université Paris Cité, Paris, France.

⁶Institut Curie, Department of Theranostic and Diagnostic Medicine, University Paris-Sciences Lettres, Paris, France.

⁷Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Paris and Saint-Cloud, France; Computational Oncology, PSL Research University, Mines Paris Tech, INSERM U1331, Paris, France.

⁸Institut Curie, Department of Theranostic and Diagnostic Medicine, University Paris-Sciences Lettres, Paris, France; INSERM U1339, Institut CURIE, Paris, France.

⁹Department of Drug Development and Innovation (D3i), Institut Curie, Paris-Saclay University, Paris, France; Computational Oncology, PSL Research University, Mines Paris Tech, INSERM U1331, Paris, France; Paris-Saclay University, Paris, France.

¹⁰Department of Medical Oncology, Institute Curie, Paris and Saint-Cloud, France; Circulating Tumor Biomarkers Laboratory, CIC Inserm 1428, Paris, France; Versailles Saint Quentin University, Saint-Cloud, France. Electronic address: francois-clement.bidard@curie.fr.

PubMed DOI

Abstract

BACKGROUND: Current treatment guidelines for patients diagnosed with stage II to III triple-negative breast cancer (TNBC) rely on the use of neoadjuvant therapy (NAT). A critical unmet need is a sensitive test that can inform the presence of distant micrometastases to help personalize postneoadjuvant systemic therapy beyond pathological complete response (pCR). PATIENTS AND METHODS: In this study…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.